The Birmingham Women's and Children's NHS Foundation Trust is responsible for managing Birmingham Women's Hospital and Birmingham Children's Hospital. It was created by a merger of Birmingham Women's NHS Foundation Trust with Birmingham Children's Hospital NHS Foundation Trust in February 2017.

During the past decade, Birmingham Women's Hospital conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Birmingham Women's Hospital" #1 sponsor was "Birmingham Women's NHS Foundation Trust" with 5 trials, followed by "Bayer" with 2 trials sponsored, "Birmingham Women's and Children's NHS Foundation Trust" with 2 trials sponsored, "Thayyil, Sudhin" with 2 trials sponsored and "University of Edinburgh" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Birmingham Women's Hospital" #1 collaborator was "NHS Lothian" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "The Leeds Teaching Hospitals NHS Trust" with 2 trials as a collaborator, "University of Birmingham" with 2 trials as a collaborator and "Barts & The London NHS Trust" with 1 trials as a collaborator. Other collaborators include 44 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "Birmingham Women's Hospital" are "Female Pelvic Examination" (2 trials), "Neonatal Encephalopathy" (2 trials), "Pregnancy" (2 trials), "Retinopathy of Prematurity (ROP)" (2 trials) and "Analgesia" (1 trials). Many other conditions were trialed in "Birmingham Women's Hospital" in a lesser frequency.

Most popular intervention types in "Birmingham Women's Hospital" are "Procedure" (11 trials), "Drug" (7 trials), "Device" (6 trials), "Other" (3 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Eylea (Aflibercept, BAY86-5321)" (2 trials), "Laser photocoagulation" (2 trials), "A package of interventions" (1 trials), "Antibiotic" (1 trials) and "Arabin Cervical Pessary" (1 trials). Other intervention names were less common.

The vast majority of trials in "Birmingham Women's Hospital" are 16 trials for "Female" genders, 10 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Birmingham Women's Hospital". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Birmingham Women's Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Birmingham Women's Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 12 trials that are defined as “Not Applicable".